Tolerability of Peginterferon Plus Ribavirin for Chronic Hepatitis C and HIV for Patients Receiving Antiretroviral Medication vs Not Receiving Antiretroviral Medication
Chronic Hepatitis C, HIV Infections
About this trial
This is an interventional treatment trial for Chronic Hepatitis C focused on measuring peg interferon, ribavirin, HAART, HIV, Chronic Hepatitis C, Treatment Experienced
Eligibility Criteria
Inclusion Criteria: Hepatitis C genotype 1 infection· Detectable plasma HCV-RNA Roche>1000copies/ml, >600IU/ml Chronic liver disease consistent with CHC infection on a biopsy obtained within the past 24 months Patients with cirrhosis or incomplete cirrhosis must have an abdominal ultrasound, CT scan, or MRI scan without evidence of hepatocellular carcinoma and a serum AFP <100 ng/mL within 2 months of randomization Patients with CD4 cell count ³ 350 cells /µL Patients on stable highly active antiretroviral therapy (HAART) for at least 12 weeks prior to baseline with the exception of patients receiving didanosine HIV-1 RNA is < 5000 copies/mL Exclusion Criteria: IFN, pegylated interferons, viramidine, levovirin, or ribavirin therapy at any previous time Patients with evidence of active hepatitis B infection. ( presence of HbsAg) History or evidence of decompensated liver disease and/or a Child-Pugh score > 5, bleeding from esophageal varices, hepatic malignancy abnormal bloodwork ie absolute neutrophil <1,Hbg <110, Platelets <70,creatinine <50
Sites / Locations
- University Health Network, Toronto General Hospital